Raxibacumab
Phase 2/3Completed 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Treatment of Inhalation Anthrax
Conditions
Therapeutic Treatment of Inhalation Anthrax
Trial Timeline
Jan 31, 2008 → May 31, 2008
NCT ID
NCT02016963About Raxibacumab
Raxibacumab is a phase 2/3 stage product being developed by Emergent BioSolutions for Therapeutic Treatment of Inhalation Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT02016963. Target conditions include Therapeutic Treatment of Inhalation Anthrax.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02016963 | Phase 2/3 | Completed |
Competing Products
11 competing products in Therapeutic Treatment of Inhalation Anthrax
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) | Johnson & Johnson | Phase 1 | 33 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine | Pfizer | Phase 1 | 32 |
| BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 | Bayer | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |